• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACHC alert in real time by email

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno.

    "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth."

    Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:ACHC), a leader in the behavioral healthcare industry, where he drove financial discipline and operational performance across its network. Before Acadia, Young served as EVP and CFO at Elanco (NYSE:ELAN), one of the world's largest independent animal health companies, where he played a central role in establishing the company as an independent public entity following its separation from Eli Lilly.

    "NVA has built something truly special for veterinarians, pet families, and the animals they love," said Young. "I am honored to join and look forward to partnering with John and the team to strengthen the financial foundation that drives continued value creation."

    Young's appointment reflects NVA's continued investments across its care network as the company builds toward its next chapter.

    About NVA

    National Veterinary Associates is defining the future of animal care. NVA is a community of 1,300 care centers across North America, including general practice veterinary hospitals, equine hospitals, pet resorts, and specialty and emergency expertise through Ethos Veterinary Health. For more information, visit www.nva.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260424515030/en/

    Media Contact

    Michelle Reardon

    Michelle.Reardon@nva.com

    Get the next $ACHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHC
    $ELAN

    CompanyDatePrice TargetRatingAnalyst
    Acadia Healthcare Company Inc.
    $ACHC
    6/3/2026$30.00Hold → Buy
    Jefferies
    Acadia Healthcare Company Inc.
    $ACHC
    5/4/2026$39.00Outperform → Strong Buy
    Raymond James
    Elanco Animal Health Incorporated
    $ELAN
    4/15/2026$30.00Buy
    Citigroup
    Acadia Healthcare Company Inc.
    $ACHC
    1/22/2026$15.00Buy → Hold
    Jefferies
    Elanco Animal Health Incorporated
    $ELAN
    1/22/2026Neutral → Overweight
    Piper Sandler
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Acadia Healthcare Company Inc.
    $ACHC
    12/3/2025$14.00Outperform → Market Perform
    Leerink Partners
    Acadia Healthcare Company Inc.
    $ACHC
    12/3/2025$13.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $ACHC
    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Acadia Healthcare upgraded by Jefferies with a new price target

    Jefferies upgraded Acadia Healthcare from Hold to Buy and set a new price target of $30.00

    6/3/26 8:05:16 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare upgraded by Raymond James with a new price target

    Raymond James upgraded Acadia Healthcare from Outperform to Strong Buy and set a new price target of $39.00

    5/4/26 8:30:20 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Elanco Animal Health with a new price target

    Citigroup initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $30.00

    4/15/26 8:08:24 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Modi Rajeev A. bought $99,939 worth of shares (4,911 units at $20.35), increasing direct ownership by 3% to 160,812 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:39:20 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $99,843 worth of shares (4,971 units at $20.09) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    5/19/26 4:38:26 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/16/26 4:33:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/16/26 4:31:38 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    6/16/26 4:31:05 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer

    National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. "I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ:AC

    4/24/26 9:00:00 AM ET
    $ACHC
    $ELAN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Acadia Healthcare Appoints David Duckworth as Interim Chief Financial Officer

    Reaffirms Financial Guidance for First Quarter and Full Year 2026 Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced the appointment of David Duckworth, former Chief Financial Officer of Acadia, as Interim Chief Financial Officer, effective May 1, 2026. Duckworth succeeds Todd Young, who is departing from the Company to pursue a CFO role at a private equity-backed animal health company. Young will remain with the Company through April 30, 2026, and will participate in the Company's first quarter earnings call scheduled for the morning of April 30. Debra K. Osteen, Chief Executive Officer of Acadia, said, "We are pleased to welcome David back as Int

    4/23/26 4:15:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Acadia Healthcare Appoints Daniel Cancelmi to Board of Directors

    Wade D. Miquelon to Retire from the Board at Upcoming Annual Meeting Acadia Healthcare Company, Inc. (NASDAQ:ACHC) ("Acadia") today announced that it has appointed Daniel Cancelmi to its Board of Directors, effective immediately. Mr. Cancelmi is a seasoned finance leader with an expansive knowledge of healthcare and a proven track record of driving superior financial performance. Most recently, he served as Executive Vice President and Chief Financial Officer of Tenet Healthcare Corporation, where he played a significant role in the company's transformation and in strengthening its balance sheet. Over the course of his three-decade career at Tenet, he held a range of finance roles of in

    3/12/26 4:15:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/14/24 1:28:32 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/12/24 9:50:14 AM ET
    $ACHC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acadia Healthcare Company Inc.

    SC 13G/A - Acadia Healthcare Company, Inc. (0001520697) (Subject)

    11/8/24 10:52:39 AM ET
    $ACHC
    Medical Specialities
    Health Care

    $ACHC
    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Animal Health Reports First Quarter 2026 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetFirst Quarter 2026 Financial Results:Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growthReported Net Income of $57 million, Adjusted Net Income of $204 millionAdjusted EBITDA of $334 million; Adjusted EBITDA Margin of 24.5%Reported EPS of $0.11, Adjusted EPS of $0.40Net leverage ratio of 3.5x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.2 billionRaising revenue guidance to $5,010 million to $5,085 million, or 5% to 7% organic constant currency growthRaising Adjusted EBITDA to $975 million to $1,005 million, a year-over-y

    5/6/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Healthcare Announces First Quarter 2026 Results

    Company Increases Full Year 2026 Adjusted EBITDA and Adjusted EPS Guidance Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Results Revenue totaled $828.8 million, a 7.6% increase compared with the first quarter of 2025 Same-facility revenue increased 7.3% compared with the first quarter of 2025, including an increase in revenue per patient day of 5.6% and an increase in patient days of 1.6% Net income attributable to Acadia totaled $0.05 per diluted share, compared with $0.09 per diluted share in the prior-year period Adjusted net income attributable to

    4/29/26 4:05:00 PM ET
    $ACHC
    Medical Specialities
    Health Care

    Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement

    INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.asp

    4/16/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health

    New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutionsINDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture capital (CVC) platform designed to support, invest and advance innovation in animal health. To be backed by a $25 million multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector."From pets to protein – the animal health industry has

    6/18/26 7:26:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs

    TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume doseBy combining two injections into one, the vaccine minimizes "pokes" supporting comfortable wellness visits for petsFeatures proprietary PureFil™ Technology, designed to reduce vaccination reactions associated with unwanted proteini,ii,iiiProduct expected to begin shipping in the next 30 daysINDIANAPOLIS, June 15, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Department of Agriculture (USDA) approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient

    6/15/26 8:47:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm

    Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today reaffirms its commitment to providing veterinarians, livestock produ

    6/4/26 6:26:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHC
    $ELAN
    SEC Filings

    View All

    SEC Form SD filed by Elanco Animal Health Incorporated

    SD - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:09:19 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    5/27/26 5:00:57 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Acadia Healthcare Company Inc.

    8-K - Acadia Healthcare Company, Inc. (0001520697) (Filer)

    5/18/26 5:15:03 PM ET
    $ACHC
    Medical Specialities
    Health Care